<![CDATA[Practical Toxicity Monitoring and Multidisciplinary Management in HER2-Positive Metastatic Breast Cancer]]>

Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy

Methylation-based ctDNA monitoring in 57 patients closely reflects outcomes in ER+, HER2- metastatic breast cancer during CDK4/6 inhibitor t

Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy

Conditions : Breast Cancer Sponsors : Zhejiang Cancer Hospital Not yet recruiting

<![CDATA[From Observation to Treatment: The Role of Caregivers and Overcoming VMAT2 Inhibitor Complexities]]>

Ribociclib Plus Aromatase Inhibitor Delays Postprogression Events in HR+/HER2− Metastatic Breast Cancer

For patients with hormone receptor-positive, HER2-negative metastatic breast cancer, endocrine therapy combined with a CDK4/6 inhibitor has

T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

Conditions : Advanced Breast Cancer; Metastatic Breast Cancer; HER2 Positive; HR Positive Interventions : Drug: Trastuzumab deruxtecan; Drug

<![CDATA[AI Test Predicts Breast Cancer Recurrence Using Standard Pathology Slides]]>